Does Humana Cover Evenity (Romosozumab)?

How Humana Classifies Evenity on Its Formulary

Humana places Evenity (romosozumab-aqqg) on its specialty formulary tier across both commercial and Medicare Advantage (MA) plans. Specialty tier typically means Tier 4 or Tier 5, with coinsurance ranging from 25% to 33% of the drug's cost rather than a flat copay. At a list price near $1,825 per month, that translates to $450 to $600 per injection before any manufacturer assistance or plan-specific caps.

Formulary placement varies by specific Humana product. Members enrolled in Humana Gold Plus HMO plans may see different cost-sharing than those on Humana Choice PPO or Humana MarketPoint plans. The 2025 and 2026 Medicare Part D redesign introduced a $2,000 annual out-of-pocket cap for prescription drugs, which benefits MA members prescribed high-cost specialty biologics like romosozumab. Humana commercial plans do not carry this federal cap, so total exposure over the 12-month treatment course can exceed $5,000 without supplemental assistance.

Romosozumab earned FDA approval in April 2019 for the treatment of osteoporosis in postmenopausal women at high fracture risk. The approval was supported by the FRAME trial (N=7,180), which demonstrated a 73% reduction in new vertebral fractures at 12 months versus placebo. Humana's coverage criteria track this FDA-labeled indication closely, and off-label use (such as for male osteoporosis or glucocorticoid-induced bone loss) faces higher denial rates.

Prior Authorization Criteria for Evenity on Humana

Humana requires prior authorization for every Evenity prescription. The process is moderate in difficulty for patients who meet clinical criteria and substantially harder for those without complete documentation. Approval hinges on three pillars: diagnosis confirmation, fracture risk documentation, and step therapy compliance.

Humana's clinical review team typically requires a DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip. Alternatively, a T-score between -1.0 and -2.5 paired with a FRAX 10-year probability of major osteoporotic fracture exceeding 20% or hip fracture probability above 3% may qualify. A history of fragility fracture documented by imaging strengthens the case considerably.

The prescribing clinician must also confirm that romosozumab is appropriate from a cardiovascular safety standpoint. The ARCH trial (N=4,093) comparing romosozumab to alendronate showed a 48% reduction in new vertebral fractures at 24 months but also revealed a higher rate of serious cardiovascular events in the romosozumab group (2.5% vs. 1.9%). The FDA boxed warning states romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Humana's prior authorization form now asks prescribers to attest that no such recent cardiovascular event has occurred.

Documentation submitted to Humana should include the DXA report with T-scores, FRAX calculation output, imaging confirming any prior fractures, a cardiovascular risk attestation, and records of prior osteoporosis therapy trials. Incomplete submissions are the leading cause of delays.

Step Therapy Requirements Before Humana Approves Evenity

Humana enforces step therapy for Evenity on both commercial and MA plans. Most Humana formulary protocols require documented use of at least one first-line antiresorptive agent before romosozumab can be authorized.

The typical step therapy sequence requires a trial of an oral bisphosphonate such as alendronate (70 mg weekly) or risedronate for a minimum of 12 months. If oral bisphosphonates are contraindicated due to esophageal disorders, renal impairment (GFR <35 mL/min), or documented intolerance, Humana may accept a trial of zoledronic acid (5 mg IV annually) or denosumab (60 mg subcutaneously every 6 months) as step therapy fulfillment.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend that patients at very high fracture risk, defined as those with a recent fracture within the past 12 months, T-score below -3.0, or multiple vertebral fractures, should receive anabolic therapy first rather than antiresorptive agents. This recommendation can be cited in a step therapy exception request. Humana has granted step therapy overrides when the prescriber provides AACE-aligned justification showing the patient meets very-high-risk criteria.

Patients who have fractured while on bisphosphonate therapy have the strongest case for bypassing step therapy entirely. A new fracture during active antiresorptive treatment represents treatment failure by any clinical standard.

What Happens When Humana Denies Evenity Coverage

Denial rates for Evenity on Humana MA plans are higher than on commercial plans, partly because MA plans apply CMS-specific utilization management rules. When a denial arrives, the explanation of benefits (EOB) letter specifies whether the denial is based on medical necessity, formulary exclusion, or incomplete documentation.

The first step after denial is an internal appeal filed within 60 days (180 days for Medicare Advantage). The appeal should include a letter of medical necessity from the prescribing physician referencing the ARCH trial data showing that romosozumab reduced new vertebral fracture risk by 48% compared to alendronate at 24 months and reduced hip fracture risk by 38%. Including the patient's specific T-scores, fracture history, and documentation of prior therapy failure strengthens the appeal.

If the internal appeal is denied, MA members can request an independent review through the MAXIMUS federal contractor within 60 days of the denial. MAXIMUS reviews are binding on Humana. The prescriber's letter should explicitly cite the Endocrine Society Clinical Practice Guidelines recommending anabolic therapy for patients at very high fracture risk, and the FDA approval data supporting romosozumab's fracture reduction efficacy.

Commercial plan denials follow a different track. After exhausting internal appeals, members may file a complaint with their state insurance commissioner or pursue external review through an independent review organization (IRO) as mandated by the Affordable Care Act external review provisions.

Cost-Reduction Strategies for Evenity Under Humana

Romosozumab is expensive. At $1,825 per monthly dose over 12 months, the total course costs approximately $21,900 at list price. Several strategies can reduce out-of-pocket burden for Humana members.

Amgen's Assist 360 program offers copay assistance for commercially insured patients, potentially reducing monthly costs to as low as $0 to $5 per injection. This program does not apply to Medicare, Medicaid, or other federally funded plan members due to anti-kickback statutes. Commercially insured Humana members should enroll before their first injection.

For Medicare Advantage members, the Medicare Part D $2,000 annual out-of-pocket cap implemented under the Inflation Reduction Act provides meaningful relief. Once a member reaches $2,000 in true out-of-pocket spending during the calendar year, cost-sharing drops to zero for the remainder of the year. Given Evenity's monthly cost, most MA members will hit this cap within the first two to three months of treatment, making the remaining 9 to 10 doses effectively free.

Patient assistance foundations such as the HealthWell Foundation and the Patient Access Network Foundation occasionally offer grants for osteoporosis medications that cover copays and coinsurance. Availability fluctuates. Checking these programs quarterly is worthwhile because fund balances reset periodically.

Some Humana plans also offer a specialty pharmacy concierge service. Working through Humana's preferred specialty pharmacy (often CenterWell Specialty Pharmacy) can sometimes reveal plan-specific discounts or faster prior authorization processing compared to using an external specialty pharmacy.

Clinical Evidence Supporting Evenity for High-Risk Osteoporosis

Humana's coverage criteria are built on the clinical trial evidence supporting romosozumab. Two large randomized controlled trials form the foundation.

The FRAME trial (N=7,180) enrolled postmenopausal women with T-scores between -2.5 and -3.5 at the total hip or femoral neck. At 12 months, romosozumab 210 mg monthly reduced new vertebral fractures by 73% versus placebo (0.5% vs. 1.8%, P<0.001). The benefit extended through 24 months when patients transitioned to denosumab, with a 75% reduction in vertebral fractures compared to those who received placebo followed by denosumab.

The ARCH trial (N=4,093) compared romosozumab for 12 months followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (6.2% vs. 11.9%, P<0.001) and hip fractures by 38% (2.0% vs. 3.2%, P=0.02) compared to alendronate alone.

Romosozumab works through a dual mechanism: it is a monoclonal antibody that binds sclerostin, simultaneously increasing bone formation and decreasing bone resorption. This dual action produces rapid gains in bone mineral density (BMD). In FRAME, lumbar spine BMD increased by 13.3% at 12 months with romosozumab versus 0.0% with placebo.

The anabolic window is limited. Romosozumab's bone-forming effect attenuates after 12 monthly doses due to the natural feedback loop in the Wnt signaling pathway. This is why the FDA label limits treatment to 12 doses and why Humana will not authorize extensions beyond this period. Transition to an antiresorptive agent (typically denosumab or zoledronic acid) after the 12-month course is standard practice, as recommended by the AACE 2020 guidelines.

Cardiovascular Safety Considerations That Affect Humana Approval

The cardiovascular signal from the ARCH trial directly shapes Humana's prior authorization criteria. In ARCH, adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of the romosozumab group versus 1.9% in the alendronate group over the 12-month active treatment period. The difference did not reach statistical significance in the overall population but prompted the FDA to add a boxed warning.

Humana's prior authorization form now includes a cardiovascular risk screening section. Prescribers must confirm the patient has not had a myocardial infarction or stroke within the prior 12 months and must document the patient's cardiovascular risk profile. Some Humana MA plans additionally require documentation of a recent lipid panel and blood pressure reading.

The FRAME trial, which compared romosozumab to placebo rather than an active comparator, did not show a similar cardiovascular signal (MACE: 1.33% romosozumab vs. 1.19% placebo). Whether the ARCH finding represents a true romosozumab risk or a protective effect of alendronate remains debated. A 2020 meta-analysis of both trials concluded the cardiovascular risk was uncertain and likely small in absolute terms but recommended caution in patients with pre-existing cardiovascular disease.

For Humana approval purposes, the practical implication is straightforward: patients with recent cardiovascular events will be denied, and prescribers should proactively address cardiovascular history in the authorization request.

Transition Planning After the 12-Month Evenity Course

Humana authorizes Evenity for a maximum of 12 monthly doses, consistent with the FDA label. Planning for post-romosozumab antiresorptive therapy should begin by month 8 or 9 to avoid a gap in treatment.

The FRAME extension data showed that transitioning from romosozumab to denosumab maintained and extended BMD gains, with lumbar spine BMD reaching 17.6% above baseline at 24 months. Transitioning to placebo (no follow-on therapy) resulted in partial loss of the BMD gained during the romosozumab phase. The Endocrine Society guidelines recommend against stopping anabolic therapy without initiating antiresorptive consolidation.

Humana typically covers denosumab and zoledronic acid with less restrictive prior authorization than romosozumab, making the transition logistically simpler. The prescribing team should submit the follow-on prior authorization while the patient is still receiving romosozumab to prevent coverage gaps that could compromise the BMD gains achieved during the anabolic phase.

Repeat DXA scanning to document treatment response is generally recommended 12 to 24 months after initiating therapy and can serve as supporting documentation for continued antiresorptive coverage.